RT Journal Article
SR Electronic
T1 Effect of polymerized type I collagen in hyperinflammation of adult outpatients with symptomatic COVID-19: a double blind, randomised, placebo-controlled clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.12.21257133
DO 10.1101/2021.05.12.21257133
A1 Méndez-Flores, Silvia
A1 Priego-Ranero, Ángel
A1 Azamar-Llamas, Daniel
A1 Olvera-Prado, Héctor
A1 Rivas-Redondo, Kenia Ilian
A1 Ochoa-Hein, Eric
A1 Perez-Ortiz, Andric
A1 Rojas-Castañeda, Estefano
A1 Urbina-Terán, Said
A1 Septién-Stute, Luis
A1 Hernández-Gilsoul, Thierry
A1 Aguilar-Morgan, Adrián Andrés
A1 Fernández-Camargo, Dheni A.
A1 Olivares-Martínez, Elizabeth
A1 Hernández-Ramírez, Diego F.
A1 Torres-Villalobos, Gonzalo
A1 Furuzawa-Carballeda, Janette
YR 2021
UL http://medrxiv.org/content/early/2021/05/17/2021.05.12.21257133.abstract
AB BACKGROUND Currently, therapeutic options for ambulatory COVID-19 patients are limited.OBJECTIVE To evaluate the safety, efficacy and effect of the intramuscular administration of polymerized type I collagen (PTIC) on hyperinflammation, oxygen saturation and symptom improvement in adult outpatients with symptomatic COVID-19.DESIGN Double-blind, randomised, placebo-controlled clinical trial of PTIC vs placebo.SETTING Single Third-level hospital in Mexico City (Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán)PARTICIPANTS Eighty-nine adult participants with a confirmed COVID-19 diagnosis and symptom onset within the 7 days preceding recruitment were included from August 31, 2020 to November 7, 2020 and followed for 12 weeks. Final date of follow-up was February 4, 2021.INTERVENTIONS Patients were randomly assigned to receive either 1.5 ml of PTIC intramuscularly every 12 h for 3 days and then every 24 h for 4 days (n=45), or matching placebo (n=44).MAIN OUTCOMES AND MEASURES The primary outcome was a mean reduction of at least 50% in the level of IP-10 compared to baseline. The secondary outcomes were mean oxygen saturation ≥92% while breathing ambient air and duration of symptoms.RESULTS Of 89 patients who were randomised, 87 (97.8%) were included in an intention-to-treat analysis; 37 (41.6%) were male and mean age was 48.5±14.0 years. The IP-10 levels decreased 75% in the PTIC group and 40% in the placebo group vs baseline. The comparison between treatment vs placebo was also statistically significant (P=0.0047). The IL-8 (44%, P=0.045), M-CSF (25%, P=0.041) and IL-1Ra (36%, P=0.05) levels were also decreased in the PTIC group vs baseline. Mean oxygen saturation ≥92% was achieved by 40/44 (90%), 41/42 (98%) and 40/40 (100%) of participants that received PTIC at 8, 15 and 97 days of follow-up vs 29/43 (67%), 31/39 (80%) and 33/37 (89%) of patients treated with placebo (P=0.001). The unadjusted accelerated failure time model showed that patients treated with PTIC achieved the primary outcome 2.70-fold faster (P<0.0001) than placebo. In terms of risk, the group of patients treated with PTIC had a 63% lower risk of having a mean oxygen saturation <92% vs placebo (P<0.0001). Symptom duration in patients treated with PTIC was reduced by 6.1±3.2 days vs placebo. No differences in adverse effects were observed between the groups at 8, 15 and 97 days of follow-up.CONCLUSIONS In this study, treatment with PTIC down-regulated IP-10, IL-8, M-CSF and IL-Ra levels, which could explain the PTIC effect on the higher proportion of patients with mean oxygen saturation readings ≥92% and a shorter duration of symptoms as compared to patients treated with placebo. Although results are encouraging, larger randomised trials are needed.TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT04517162Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04517162Funding StatementThe funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review board of the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ, reference no. IRE 3412-20-21-1; supplement 1) and was conducted in compliance with the Declaration of Helsinki,20 the Good Clinical Practice guidelines, and local regulatory requirements. All participants provided written informed consent. This study is registered with the ClinicalTrials.gov identifier NCT04517162.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Sharing Statement: In accordance with NHS Digital Information Governance requirements, the study data cannot be shared. The manuscript guarantor affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.